AstraZeneca Pharma Gets CDSCO Nod To Market Imfinzi For New Cancer Indication

AstraZeneca Pharma India Ltd. on Monday said it has received approval from the Central Drugs Standard Control Organisation (CDSCO) to import and market Durvalumab solution, sold under the brand name Imfinzi, for an additional cancer indication.

This latest approval allows the company to market Imfinzi in combination with gemcitabine and cisplatin for the treatment of adult patients with muscle invasive bladder cancer, AstraZeneca said in an exchange filing.

Earlier this month, the company had received approval for Imfinzi in combination with carboplatin and paclitaxel for first-line treatment of adults with primary advanced or recurrent endometrial cancer.